2017•Clinical & Translational OncologyRequires access

Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it

Maria Drizou, Ηλίας Κοττέας, Nikolaos Syrigos

Open publisher page 24 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 24 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Crizotinib, Alectinib, Ceritinib, Anaplastic lymphoma kinase, Medicine, Lung cancer, ALK inhibitor, Oncology

Back to paper search Browse research topics Original source

Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it — Research Paper | ScholarLens